

# **CLINICAL PRACTICE GUIDELINES**

## **Nutrition in CKD**

**UK Renal Association**

**5<sup>th</sup> Edition, 2009-2010**

**Draft Version (22.01.10)**

**Dr Mark Wright and Dr Colin Jones**

**Posted at [www.renal.org/guidelines](http://www.renal.org/guidelines)**

**Please check for updates**

Please send feedback for the next edition to  
Dr Mark Wright at [Mark.wright@leedsth.nhs.uk](mailto:Mark.wright@leedsth.nhs.uk) and  
Dr Colin Jones at [Colin.H.Jones@York.nhs.uk](mailto:Colin.H.Jones@York.nhs.uk)

## **Contents**

### **Introduction**

#### **Summary of clinical practice guideline for nutrition in CKD**

1. Screening for undernutrition in CKD (Guidelines 1.1- 1.2)
2. Prevention of undernutrition in CKD (Guidelines 2.1- 2.6)
3. Treatment of established undernutrition in CKD (Guidelines 3.1 – 3.6)
4. Nutritional support in AKI (see AKI guideline 10.1-10.4)

#### **Summary of audit measures for nutrition in CKD**

Audit measures 1-9

#### **Rationale for clinical practice guideline for nutrition in CKD**

1. Screening for undernutrition in CKD (Guidelines 1.1- 1.2)
2. Prevention of undernutrition in CKD (Guidelines 2.1- 2.6)
3. Treatment of established undernutrition in CKD (Guidelines 3.1 – 3.6)

## Introduction

Malnutrition in chronic kidney disease (CKD) is common but is often undiagnosed. This evidence-based clinical practice guideline summarises the main interventions that may be recommended in the prevention and management of undernutrition in this patient population. Undernutrition is a more frequent finding in established renal failure (ERF) (present in 30-40% of patients)<sup>1</sup> and is associated with reduced patient survival. The guideline authors regularly search for and evaluate the nutrition literature and are familiar with the literature pertaining to nutrition and renal disease. The extensive North American (K-DOQI 2000) and European (Locatelli et al 2002) guidelines on the assessment of nutrition in renal patients<sup>2,3</sup> were reviewed and primary sources examined as appropriate. This document offers a reinterpretation and update of those guidelines and incorporates recent UK Department of Health initiatives on nutritional screening<sup>4</sup>.

## References

1. Ikizler TA, Hakim RM. Nutrition in end-stage renal disease. *Kidney Int* 1996;50:343-357
2. NKF-DOQI clinical practice guidelines for nutrition in chronic renal failure. *American Journal of Kidney Diseases* 2000;35(S2):S17-S104 (<http://www.kidney.org/professionals/kdoqi/pdf/KDOOI2000NutritionGL.pdf>).
3. Locatelli F, Fouque D, Heimbürger O, Drüeke TB, Cannata-Andía JB, Hörl WH, Ritz E. Nutritional status in dialysis patients: a European consensus. *Nephrol Dial Transplant* 2002;17:563-572
4. Department of Health. Improving nutritional care: a joint action plan from the Department of Health and Nutrition Summit stakeholders 2007. [http://www.dh.gov.uk/prod\\_consum\\_dh/groups/dh\\_digitalassets/@dh/@en/documents/digitalassets/dh\\_079932.pdf](http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalassets/dh_079932.pdf)

## Summary of clinical practice guidelines for nutrition in CKD

### 1. Screening for undernutrition in CKD (Guidelines 1.1 – 1.2)

#### Guideline 1.1.1 – Screening methods for undernutrition in CKD

We recommend that all patients with stage 4-5 CKD should have the following parameters measured as a minimum in order to identify undernutrition (1C):

- Actual Body Weight (ABW) (< 85% of Ideal Body Weight (IBW))
- Reduction in oedema free body weight (of 5% or more in 3 months or 10% or more in 6 months)
- BMI (<20kg/m<sup>2</sup>)
- Subjective Global Assessment (SGA) (B/C on 3 point scale or 1-5 on 7 point **scale**)

The above simple audit measures have been linked to increased mortality and other adverse outcomes.

#### Guideline 1.1.2 – Screening methods for undernutrition in CKD

We suggest that other measures including bioimpedance analysis, anthropometry and assessment of nutrient intake can help to detect those who are at risk of developing or have developed undernutrition (GRADE 2B). Low serum albumin is a strong predictor of adverse outcomes, but it is not entirely related to nutritional status.

### **Guideline 1.2 – Frequency of screening for undernutrition in CKD**

We recommend that screening should be performed (1D);

- Weekly for inpatients
- 2-3 monthly for outpatients with eGFR <20 but not on dialysis
- Within one month of commencement of dialysis then 6-8 weeks later
- 4-6 monthly for stable haemodialysis patients
- 4-6 monthly for stable peritoneal dialysis patients

## **2. Prevention of undernutrition in CKD (Guidelines 2.1 – 2.6)**

### **Guideline 2.1 – Small solute dose to prevent undernutrition**

We recommend that dialysis dose meets recommended solute clearance index guidelines (e.g. Kt/V) (1C)

### **Guideline 2.2 – Correction of metabolic acidosis and nutrition**

We recommend that venous bicarbonate concentrations should be maintained above 22 mmol/l (1C)

### **Guideline 2.3 – Minimum daily dietary protein intake**

We suggest a prescribed protein intake of:

- 0.75 g/kg IBW/day for patients with stage 4-5 CKD not on dialysis
- 1.2 g/kg IBW/day for patients treated with dialysis (2B)

### **Guideline 2.4 – Recommended daily energy intake**

We suggest a prescribed energy intake of

- 30-40 kcal/kg IBW/day for all patients depending upon age and physical activity (2B)
- Recommended nutrient intakes are designed to ensure that 97.5% of a population take in enough protein and energy to maintain their body composition. There is variation in actual nutrient requirement between individuals. This means that some patients will be well maintained with lower nutrient intakes. Regular screening will help to identify when the dietary prescription needs to be amended.

### **Guideline 2.5 – Vitamin supplementation in dialysis patients**

We recommend that haemodialysis patients should be prescribed supplements of water soluble vitamins (1C).

### **Guideline 2.6 – Exercise programs in dialysis patients**

We recommend that haemodialysis patients should be given the opportunity to participate in regular exercise programmes (1C).

Progressive resistance training and aerobic exercise have both been shown to bring about improvement in physical function and some components of Quality of Life scores.

## **3. Treatment of established undernutrition in CKD (Guidelines 3.1 – 3.6)**

### **Guideline 3.1 – General treatment of established undernutrition**

We recommend assessment by a physician to determine and treat possible underlying causes and by a specialist dietician to individualise dietary advice (1D)

### **Guideline 3.2 – Oral nutritional supplements in established undernutrition**

We recommend the use of oral nutritional supplements if oral intake below levels indicated above (1C)

### **Guideline 3.3 – Enteral nutritional supplements in established undernutrition**

We recommend the use of enteral feeding via NG tube / PEG if nutrient intake suboptimal despite oral supplements (1C)

### **Guideline 3.4 – Parenteral nutritional supplements in established undernutrition**

We suggest intradialytic parenteral nutrition (IDPN) or intraperitoneal amino acids may be considered for selected cases if tube feeding is declined or clinically inappropriate (2D).

### **Guideline 3.5 – Anabolic agents in established undernutrition**

We recommend that anabolic agents such as androgens, growth hormone or IGF-1. are not indicated in the treatment of undernutrition in adults (1D).

Androgens and growth hormone have demonstrated improvement in serum albumin levels and lean body mass but not mortality and these medications have significant side effects.

### **Guideline 3.6 – Supplementation of micronutrients in established undernutrition**

We suggest that current evidence does not support the routine use of supplements other than for identified clinical need (2C).

Deficiency of fat soluble vitamins, trace elements and carnitine are prevalent in patients with chronic kidney disease.

### **Summary of Audit Measures:**

1. Percentage of dialysis patients assessed by a renal dietician within the last 6 months
2. Percentage of dialysis patients with a dry weight of <85% ideal body weight
3. Percentage of stage 4/5 patients not on dialysis with a dry weight of <85% ideal body weight
4. Percentage of dialysis patients with a BMI <20kg/m<sup>2</sup>
5. Percentage of stage 4/5 patients not on dialysis with a BMI <20kg/m<sup>2</sup>
6. Percentage of dialysis patients assessed by SGA in the last 12 months
7. Percentage of stage 4/5 patients not on dialysis assessed by SGA in the last 12 months
8. Percentage of dialysis patients with an SGA score of B/C or 1-5 on a 7-point scale
9. Percentage of stage 4/5 patients not on dialysis with an SGA score of B/C or 1-5 on a 7-point scale

## **Rationale for clinical practice guidelines for nutrition in CKD**

### **1. Screening for undernutrition in CKD (Guidelines 1.1 – 1.2)**

#### **Guideline 1.1.1 – Screening methods for undernutrition in CKD**

We recommend that all patients with stage 4-5 CKD should have the following parameters measured as a minimum in order to identify undernutrition (1C):

- Actual Body Weight (ABW) (< 85% of Ideal Body Weight (IBW))
- Reduction in oedema free body weight (of 5% or more in 3 months or 10% or more in 6 months)
- BMI (<20kg/m<sup>2</sup>)
- Subjective Global Assessment (SGA) (B/C on 3 point scale or 1-5 on 7 point *scale*)

The above simple audit measures have been linked to increased mortality and other adverse outcomes.

#### **Guideline 1.1.2 – Screening methods for undernutrition in CKD**

We suggest that other measures including bioimpedance analysis, anthropometry and assessment of nutrient intake can help to detect those who are at risk of developing or have developed undernutrition (2B). Low serum albumin is a strong predictor of adverse outcomes, but it is not entirely related to nutritional status.

#### **Guideline 1.2 – Frequency of screening for undernutrition in CKD**

We recommend that screening should be performed (1D)

- Weekly for inpatients
- 2-3 monthly for outpatients with eGFR <20 but not on dialysis
- Within one month of commencement of dialysis then 6-8 weeks later
- 4-6 monthly for stable haemodialysis patients
- 4-6 monthly for stable peritoneal dialysis patients

#### **Audit measures**

1. Percentage of dialysis patients assessed by a renal dietician within the last 6 months
2. Percentage of dialysis patients with a dry weight of <85% ideal body weight
3. Percentage of stage 4/5 patients not on dialysis with a dry weight of <85% ideal body weight
4. Percentage of dialysis patients with a BMI <20kg/m<sup>2</sup>
5. Percentage of stage 4/5 patients not on dialysis with a BMI <20kg/m<sup>2</sup>

6. Percentage of dialysis patients assessed by SGA in the last 12 months
7. Percentage of stage 4/5 patients not on dialysis assessed by SGA in the last 12 months
8. Percentage of dialysis patients with an SGA score of B/C or 1-5 on a 7-point scale
9. Percentage of stage 4/5 patients not on dialysis with an SGA score of B/C or 1-5 on a 7-point scale

### **Rationale of screening for undernutrition in CKD (1.1-1.2)**

The principle development since the last set of Renal Association guidelines has been the production of nutrition guidelines by the Department of Health. This is intended to increase awareness of nutritional challenges faced by all patients. There are 10 markers of good nutritional care that UK hospitals should adhere to (Dept of Health 2007)<sup>1</sup>. These include:

1. Nutritional screening on admission and weekly thereafter
2. Individualised nutritional care plans
3. Recognising nutrition as a core part of a hospital's clinical governance plan
4. Patient involvement
5. Protected mealtimes
6. Ongoing staff education
7. Access to good nutrition for 24 hours every day of the week
8. Performance management of the hospital nutrition policy
9. Safe delivery of nutritional care
10. An MDT approach

Given the extra nutritional challenges faced by patients with renal failure, it is particularly important that these guidelines are implemented on renal wards. More guidance on how to screen for nutritional status is available from the National Institute of Clinical Excellence (National Collaborating Centre for Acute Care 2006)<sup>2</sup> who define malnutrition as:

1. a BMI <18.5 kg/m<sup>2</sup>
2. an unintentional weight loss >10% in 3-6 months
3. BMI <20 kg/m<sup>2</sup> AND unintentional weight loss >5% in 3-6 months

The "Malnutrition Universal Screening Tool" (MUST) developed by the British Association of Parenteral and Enteral Nutrition is recommended by both NICE and the Department of Health for population screening. The risk of malnutrition is calculated from the combination of

1. BMI
  - a. >20 = 0 points
  - b. 18.5-20 = 1 point
  - c. <18.5 = 2 points
2. Percentage unplanned weight loss of

- a. <5% = 0 points
  - b. 5-10% = 1 point
  - c. >10% = 2 points
3. Presence of acute illness and no nutritional intake for 5 days = 2 points

A score of 0 is defined as low risk, 1 medium risk and 2 or more high risk. Patients at medium risk should be monitored regularly. Patients with a high risk should be actively managed. This simple system has the advantage of being easily understood by all staff but BMI calculations are not always possible or are compromised in amputees and rapid changes of weight with water removal mean that an extra level of interpretation is needed for renal patients. There are modified screening tools used by some renal dietitians.

In dialysis populations, a number of other measures that at least partially reflect nutritional state predict worsened patient survival. These include serum creatinine (Lowrie and Lew 1990)<sup>3</sup> (creatinine is dependent on both renal function and muscle mass), serum cholesterol (Lowrie and Lew 1990)<sup>3</sup>, serum albumin (Lowrie and Lew 1990<sup>3</sup>, Blake et al 1993)<sup>4</sup>, subjective global assessment (CANUSA 1996)<sup>5</sup>, body mass index (Kopple et al 1999)<sup>6</sup>, lean body mass (CANUSA 1996)<sup>5</sup>, and handgrip strength (Heimbürger et al 2000)<sup>7</sup>. This decrease in survival has been attributed to poor nutrition, however there is a strong correlation between inflammation, atherosclerosis and poor nutrition, referred to as the MIA complex (Stenvinkel 2001)<sup>8</sup>. The association between a low serum albumin and poor survival of dialysis patients predominantly reflects the association between serum albumin and inflammation (Kaysen et al 2000)<sup>9</sup>, co-morbidity (Davies et al 1995)<sup>10</sup> and fluid overload (Jones 2001)<sup>11</sup>.

As there is no single 'gold standard' measure of nutritional state, a panel of measurements should be used, reflecting the various aspects of protein-calorie nutrition.

A full nutritional assessment will include a medical history, assessment of dietary intake (by recall, 3-day food diary and measurement of protein equivalent of nitrogen appearance), anthropometric measures (mid-arm muscle circumference, triceps skinfold thickness and calculated mid-arm muscle circumference), and estimation of dialysis adequacy and of residual renal function. Subjective global assessment (SGA) includes gastrointestinal symptoms (appetite, anorexia, nausea, vomiting, diarrhoea), weight change in the preceding 6 months and last 2 weeks, evidence of functional impairment and a subjective visual assessment of subcutaneous tissue and muscle mass (Enia 1993)<sup>12</sup>.

Serum albumin has been considered a marker of visceral protein and often used as a measure of nutritional state. Serum albumin is strongly predictive of mortality in pre-dialysis, dialysis and transplant populations. However the relationship between serum albumin and nutritional state is weak and in general causes other than malnutrition should be excluded (Jones et al 1997)<sup>13</sup>. Assessment might include C-reactive protein, evidence of atherosclerosis, 24-hour urinary protein loss, 24-hour peritoneal protein loss and determination of circulatory volume status by clinical examination and / or bio-electric impedance.

There is little evidence to guide the frequency of screening for dialysis patients. Assessment is needed at dialysis commencement to identify those who require nutritional supplementation as well as those who need water removal and to balance this with advice on the various dietary restrictions that may be necessary. After 6-8 weeks of dialysis, many patients have symptomatic relief and it may be that the dietary advice needs to change. For stable patients, nutritional changes are likely to be gradual after this. Mechanisms to detect patients that encounter a nutritional challenge between reviews need to be in place. The importance of multidisciplinary working between doctors, nurses and specialist dietitians in this regard cannot be over-emphasised.

## References

1. Department of Health. Improving nutritional care: a joint action plan from the Department of Health and Nutrition Summit stakeholders 2007.  
[http://www.dh.gov.uk/prod\\_consum\\_dh/groups/dh\\_digitalassets/@dh/@en/documents/digitalassets/dh\\_079932.pdf](http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalassets/dh_079932.pdf)
2. National Collaborating Centre for Acute Care. Nutrition support in adults Oral nutrition support, enteral tube feeding and parenteral nutrition. 2006  
<http://www.nice.org.uk/nicemedia/pdf/cg032fullguideline.pdf>
3. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. *Am J Kidney Dis* 1990;15:458-482
4. Blake PG, Flowerdew G, Blake RM, Oreopoulos DG. Serum albumin in patients on continuous ambulatory peritoneal dialysis--predictors and correlations with outcomes. *Journal of the American Society of Nephrology* 1993;3:1501-1507
5. CANUSA study group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. *Journal of the American Society of Nephrology* 1996;7:198-207
6. Kopple JD, Zhu X, Lew NL, Lowrie EG. Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. *Kidney Int* 1999;56(3):1136-1148
7. Heimburger O, Qureshi AR, Blaner WS, Berglund L, Stenvinkel P. Hand-grip muscle strength, lean body mass, and plasma proteins as markers of nutritional status in patients with chronic renal failure close to start of dialysis therapy. *American Journal of Kidney Diseases* 2000;36:1213-1225
8. Stenvinkel, P (2001) Inflammatory and atherosclerotic interactions in the depleted uremic patient. *Blood Purification*, 19, 1, 53-61
9. Kaysen GA, Dubin JA, Muller HG, Rosales LM, Levin NW. The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. The HEMO Study Group. *Kidney International* 2000;58:346-352
10. Davies SJ, Russell L, Bryan J, Phillips L and Russell GI. Comorbidity, urea kinetics, and appetite in continuous ambulatory peritoneal dialysis patients: their interrelationship and prediction of survival. *American Journal of Kidney Diseases* 1995;26:353-361
11. Jones CH. Serum albumin--a marker of fluid overload in dialysis patients? *Journal of Renal Nutrition* 2001;11:59-6
12. Enia G, Sicuso C, Alati G, Zoccali C. Subjective global assessment of nutrition in dialysis patients. *Nephrology Dialysis Transplantation* 1993;8:1094-1098
13. Jones CH, Newstead CG, Will EJ, Smye SW, Davison AM. Assessment of nutritional status in CAPD patients: serum albumin is not a useful measure. *Nephrology Dialysis Transplantation* 1997;12:1406-1413

## 2. Prevention of undernutrition in CKD (Guidelines 2.1 – 2.6)

### Guideline 2.1 – Small solute dose to prevent undernutrition

We recommend that dialysis dose meets recommended solute clearance index guidelines (e.g. Kt/V) (1C)

### **Guideline 2.2 – Correction of metabolic acidosis and nutrition**

We recommend that venous bicarbonate concentrations should be maintained above 22 mmol/l (1C)

### **Guideline 2.3 – Minimum daily dietary protein intake**

We suggest a prescribed protein intake of:

- 0.75 g/kg IBW/day for patients with stage 4-5 CKD not on dialysis
- 1.2 g/kg IBW/day for patients treated with dialysis (2B)

### **Guideline 2.4 – Recommended daily energy intake**

We suggest a prescribed energy intake of

- 30-40 kcal/kg IBW/day for all patients depending upon age and physical activity (2B)
- Recommended nutrient intakes are designed to ensure that 97.5% of a population take in enough protein and energy to maintain their body composition. There is variation in actual nutrient requirement between individuals. This means that some patients will be well maintained with lower nutrient intakes. Regular screening will help to identify when the dietary prescription needs to be amended.

### **Guideline 2.5 – Vitamin supplementation in dialysis patients**

We recommend that haemodialysis patients should be prescribed supplements of water soluble vitamins (1C).

### **Guideline 2.6 – Exercise programs in dialysis patients**

We recommend that haemodialysis patients should be given the opportunity to participate in regular exercise programmes (1C).

Progressive resistance training and aerobic exercise have both been shown to bring about improvement in physical function and some components of Quality of Life scores.

### **Rationale of prevention of undernutrition in CKD (2.1-2.6)**

Many factors predispose to the development of undernutrition in patients with CRF. Some, such as changes in appetite, dental problems, vomiting and diarrhoea, may be identified through the patient's medical history. A decrease in appetite secondary to either uraemia or underdialysis should be confirmed with an assessment of dietary intake, residual renal function and dialysis dose. Dialysis treatment to current Kt/V or

URR standards is associated with better nutrient intake than lower doses (Lindsay et al 1989 & Bergstrom et al 1993)<sup>1,2</sup>. Attempts to increase the small solute clearance further have not demonstrated progressive improvement (Davies et al 2000 & Rocco et al 2004)<sup>3,4</sup>. Protein intake can be obtained indirectly through the normalised equivalent of total protein nitrogen appearance (PNA) although this may give a spuriously high estimate in the presence of weight loss or active catabolism (Harty et al 1993)<sup>5</sup>. A variety of techniques are available for recording dietary intake; food intake records and dietary recall are the commonest. However many patients do not achieve these intakes and the consequences of this are not clear (Rocco et al 2002)<sup>6</sup>.

Acidosis is an established catabolic factor (Garibotto et al 1994)<sup>7</sup> and to minimise this the bicarbonate concentration of CAPD and HD patients should be maintained within target range (Movilli et al 1998)<sup>8</sup>. Bicarbonate supplementation in the low clearance clinic may also retard the progression of renal failure (de Brito-Ashurst et al 2009)<sup>9</sup>.

The recommended nutrient intakes are similar to those in other nutrition guidelines (KDOQI 2000 & Locatelli et al 2002)<sup>10,11</sup>. They are based on small studies of nitrogen balance. It is noted that recommended dietary intakes are set to ensure that 97.5% of a population take in enough protein and energy to maintain their body composition. There is variation in actual nutrient requirement between individuals. This means that some patients will be well maintained with lower nutrient intakes (Slomowitz et al 1989 & Bergstrom et al 1993)<sup>3,12</sup>.

Data from the DOPPS shows that supplements of water soluble vitamins were not widely prescribed in UK units. They were associated with significantly lower mortality rates at patient and institution level. They are inexpensive and present a low risk of toxicity, so we advise that their use should be more widespread (Fissell et al 2004)<sup>13</sup>.

Regular exercise will increase lean body mass in healthy individuals. A number of studies of aerobic and progressive resistance training in dialysis patients have shown benefits in terms of cardiovascular performance and either muscle mass or function (see Cheema et al 2005 for a review and & Cheema et al 2007)<sup>14,15</sup>. The studies are disparate in terms of regime and end-point, but there are consistent messages that patients undergoing regular training improve their strength, exercise tolerance and have a better sense of well being on Quality of Life scores.

## References

1. Lindsay RM, Spanner E. A hypothesis: the protein catabolic rate is dependent upon the type and amount of treatment in dialysed uraemic patients. *American Journal of Kidney Diseases* 1989; 13: 382-389
2. Bergstrom J, Furst P, Alvestrand A, Lindholm B. Protein and energy intake, nitrogen balance and nitrogen losses in patients treated with continuous ambulatory peritoneal dialysis. *Kidney International* 1993; 44: 1048-1057
3. Davies SJ, Phillips L, Griffiths AM, Naish PF, Russell GI. Analysis of the effects of increasing delivered dialysis treatment to malnourished peritoneal dialysis patients. *Kidney International* 2000; 57: 1743-1754

4. Rocco MV, Dwyer JT, Larive B, Greene T, Cocokram DB, Chumlea WC, Kusek JW, Leung J, Burrowes JD, McLeroy LC, Poole D, Uhlin L. The effect of dialysis dose and membrane flux on nutritional parameters in hemodialysis patients: results of the HEMO study. *Kidney International* 2004; 65: 2321-2334
5. Harty J, Boulton H, Heelis N, Uttley L, Venning M, Gokal R. Limitations of kinetic models as predictors of nutritional and dialysis adequacy in continuous ambulatory peritoneal dialysis patients. *Am J Nephrol* 1993;13:454-463
6. Rocco MV, Paranandi L, Burrowes JD, Cockram DB, Dwyer JT, Kusek JW, Leung J, Makoff R, Maroni B, Poole D. Nutritional status in the HEMO Study cohort at baseline. *Hemodialysis. American Journal of Medicine* 2002;39:245-256
7. Garibotto G, Russo R, Sofia A, Sala MR, Robaudo C, Moscatelli P, Deferrari G, Tizianello A. Skeletal muscle protein synthesis and degradation in patients with chronic renal failure. *Kidney Int* 1994;45:1432-1439
8. Movilli E, Zani R, Carli O, Sangalli L, Pola A, Camerini C, Cancarini GC, Scolari F, Feller P, Maiorca R. Correction of metabolic acidosis increases serum albumin concentrations and decreases kinetically evaluated protein intake in haemodialysis patients: a prospective study. *Nephrol Dial Transplant* 1998;13:1719-1722
9. De Brito-Ashurst I, Varaganam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. *Journal of the American Society of Nephrology* 2009; doi: 10.1681/ASN.2008111205
10. NKF-DOQI clinical practice guidelines for nutrition in chronic renal failure. *American Journal of Kidney Diseases* 2000;35(S2):S17-S104 (<http://www.kidney.org/professionals/kdoqi/pdf/KDOQI2000NutritionGL.pdf>).
11. Locatelli F, Fouque D, Heimbürger O, Drüeke TB, Cannata-Andía JB, Hörl WH, Ritz E. Nutritional status in dialysis patients: a European consensus. *Nephrol Dial Transplant* 2002;17:563-572
12. Slomowitz LA, Monteon FJ, Grosvenor M, Laidlaw S, Kopple JD. Effect of energy intake on nutritional status in maintenance haemodialysis patients. *Kidney International* 1989; 35: 704-711
13. Fissell RB, Bragg-Gresham JL, Gillespie BW, Goodkin DA, Bommer J, Saito A, Akiba T, Port FK, Young EW. International variation in vitamin prescription and association with mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). *American Journal of Kidney Disease* 2004; 44(2):293-299
14. Cheema BSB, Fiatarone Singh MA. Exercise training in patients receiving maintenance haemodialysis: a systematic review of clinical trials. *American Journal of Nephrology* 2005; 25: 352-364
15. Cheema B, Abas H, Smith B, O'Sullivan A, Chan M, Patwardhan A, Kelly J, Gillin A, Pang G, Lloyd B, Fiatarone Singh M. Progressive exercise for anabolism in kidney disease (PEAK): a randomised, controlled trial of resistance training during haemodialysis. *Journal of the American Society of Nephrology* 2007; 18: 1594-1601

### **3. Treatment of established undernutrition in CKD (Guidelines 3.1 – 3.6)**

#### **Guideline 3.1 – General treatment of established undernutrition**

We recommend assessment by a physician to determine and treat possible underlying causes and by a specialist dietician to individualise dietary advice (1D)

#### **Guideline 3.2 – Oral nutritional supplements in established undernutrition**

We recommend the use of oral nutritional supplements if oral intake below levels indicated above (1C)

#### **Guideline 3.3 – Enteral nutritional supplements in established undernutrition**

We recommend the use of enteral feeding via NG tube / PEG if nutrient intake suboptimal despite oral supplements (1C)

#### **Guideline 3.4 – Parenteral nutritional supplements in established undernutrition**

We suggest intradialytic parenteral nutrition (IDPN) or intraperitoneal amino acids may be considered for selected cases if tube feeding is declined or clinically inappropriate (2D).

#### **Guideline 3.5 – Anabolic agents in established undernutrition**

We recommend that anabolic agents such as androgens, growth hormone or IGF-1. are not indicated in the treatment of undernutrition in adults (1D).

Androgens and growth hormone have demonstrated improvement in serum albumin levels and lean body mass but not mortality and these medications have significant side effects.

#### **Guideline 3.6 – Supplementation of micronutrients in established undernutrition**

We suggest that current evidence does not support the routine use of supplements other than for identified clinical need (2C).

Deficiency of fat soluble vitamins, trace elements and carnitine are prevalent in patients with chronic kidney disease.

#### **Rationale of treatment of established undernutrition in CKD (3.1-3.6)**

There is a paucity of well conducted research examining the management of malnutrition in dialysis patients. Ideally worsening nutrition should be identified early and proactively managed. Correcting established malnutrition is difficult. All reversible factors (including inflammation and occult sepsis) should be identified and corrected. Initiation of dialysis may be required in pre-dialysis patients and dialysis treatment should be optimised. Increased dialysis dose (Ikizler et al 1996), the use of biocompatible membranes (Parker et al 1996;49:551) and ultrapure water (Shiffl et al 2001) have been associated with improved nutritional state<sup>1-3</sup>, although there are no longitudinal studies in overtly malnourished subjects. Serum bicarbonate should be within the recommended range (Stein et al 1997)<sup>4</sup>.

Dietary intake should be enhanced with ordinary foods or oral supplements (Steinvinkel 2005)<sup>5</sup>. In patients not responding to adequate dialysis and optimisation of oral intake enteral feeding may be required (Stratton et al 2005)<sup>6</sup>, either by nasogastric tube or percutaneous endoscopic gastrostomy. Intradialytic parenteral nutrition (in haemodialysis) (Foulks 1999)<sup>7</sup> and intraperitoneal amino acid supplementation (PD) (Jones et al 1998)<sup>8</sup> can be considered, although evidence of benefit is limited (Cano 2007)<sup>9</sup>. Pharmacological therapies include subcutaneous growth hormone (Johannsson et al 1999), insulin-like growth factor (Fouque et al 2000) and oral androgens (Barton et al 2002)<sup>10-12</sup>. Again evidence of benefit is limited. All of these interventions are expensive and are associated with potentially

serious side effects. Their use should be guided by local protocols with monitoring of nutritional state to demonstrate benefit.

## References

1. Ikizler TA, Greene JH, Wingard RL, Parker RA, Hakim RM. Spontaneous dietary protein intake during progression of chronic renal failure. *J Am Soc Nephrol* 1995;6:1386-1391
2. Parker TF 3rd, Wingard RL, Husni L, Ikizler TA, Parker RA, Hakim RM. Effect of the membrane biocompatibility on nutritional parameters in chronic hemodialysis patients. *Kidney Int* 1996;49:551-556
3. Schiff H, Lang SM, Stratakis D, Fisher R. Effects of ultrapure dialysis fluid on nutritional status and inflammatory markers. *Nephrol Dial Transplant* 2001;16:1863-1869
4. Stein A, Moorhouse J, Iles-Smith H, Baker F, Johnstone J, James G, Troughton, J Bircher G, Walls J. Role of an improvement in acid-base status and nutrition in CAPD patients. *Kidney International* 1997;52:1089-1095
5. Stenvinkel, P (2001) Inflammatory and atherosclerotic interactions in the depleted uremic patient. *Blood Purification*, 19, 1, 53-61
6. Stratton RJ, Bircher G, Fouque D, Stenvinkel P, de Mutsert R, Engfer M, Elia M. Multinutrient oral supplements and tube feeding in maintenance dialysis: a systematic review and meta-analysis. *Am J Kidney Dis* 2005;46:387-405
7. Foulks CJ. An evidence-based evaluation of intradialytic parenteral nutrition. *Am J Kidney Dis* 1999;33:186-192
8. Jones M, Hagen T, Boyle CA, Vonesh E, Hamburger R, Charytan C, Sandroni S, Bernard D, Piraino B, Schreiber M, Gehr T, Fein P, Friedlander M, Burkart J, Ross D, Zimmerman S, Swartz R, Knight T, Kraus A, McDonald L, Hartnett M, Weaver M, Martis L, Moran, J. Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: results of a multicenter outpatient study. *American Journal of Kidney Diseases* 1998;32:761-769
9. Cano NJ, Fouque D, Roth H *et al.* Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: a 2-year multicenter, prospective, randomized study. *Journal of the American Society of Nephrology* 2007; 18: 2583–2591
10. Johannsson G, Bengtsson BA, Ahlmen J. Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement. *Am J Kidney Dis* 1999;33:709-717
11. Fouque D, Peng SC, Shamir E, Kopple JD. Recombinant human insulin-like growth factor-1 induces an anabolic response in malnourished CAPD patients. *Kidney Int* 2000;57:646-654
12. Barton Pai A, Chretien C, Lau AH. The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients. *Clin Nephrol* 2002;58:38-46

## Acknowledgements

Dr Colin Jones and Dr Mark Wright have received sponsorship to attend national and international conferences from a number of pharmaceutical companies. They have no other financial interest or relationship with any pharmaceutical company.